



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

www.igenex.com

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

REFERRING PHYSICIAN

TEST DOCTOR

TEST PATIENT

DOB:
Gender:
Accession:
Patient ID:

Collected:
 Received:
 Reported:
 Reprinted:
 Amended:
 Corrected:

BABESIOSIS

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
Babesia PCR	Urine	Negative		
Babesia microti	Urine	Negative		
Babesia duncani				

BARTONELLOSIS

Bartonella henselae PCR	Urine	Negative		
B. henselae P				

ANAPLASMOSIS

HGA(A. phagocytophilum) PCR	Urine	Negative		
HGA PCR				

EHRlichiosis

HME(Ehrlichia chaffeensis) PCR	Urine	Negative		
HME PCR				

Testing performed at IGenX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGenX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGenX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

www.igenex.com

RICKETTSIOSIS

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
Rickettsia rickettsii and felis/typhi PCR				
Rickettsia rickettsii	Urine	Negative		
Rickettsia felis/typhi	Urine	Negative		

BORRELIOSIS - Lyme Disease

Lyme Multiplex PCR - Urine				
Urine - Genomic	Urine	Negative		
Urine - Plasmid	Urine	Negative		

BORRELIOSIS- Relapsing Fever Borrelia

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
RFBorrelia & B.burgdorferi sensu lato RealTime PCR				
Relapsing Fever Borrelia Genus*	Urine	Negative	Negative	
* detects RF Borrelia species specific DNA, including but not limited to B. hermsii, B.turicatae, B. miyamotoi, B. parkeri, B. coriaceae, B. turcica and B. recurrent				
RF Borrelia Subgroup Species**	Urine	Negative	Negative	
** detects RF Borrelia subgroup species specific DNA including but not limited to B. turicatae, B. miyamotoi, B. parkeri, B. coriaceae and B. recurrentis				
Borrelia burgdorferi sensu lato***	Urine	Negative		
*** detects B. burgdorferi sl specific DNA including but not limited to B. burgdorferi sensu stricto, B. afzelii, B. garinii, B. californiensis, B. mayonii, B. spielmanii and B. valaisiana				

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



556 Gibraltar Drive
 Milpitas, CA 95035
 T: (800) 832-3200
 F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914
 CALIFORNIA: CLF 4033
 NPI: 1396837605

www.igenex.com

BORRELIOSIS- Relapsing Fever Borrelia

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
Borrelia****	Urine	Negative	Negative	

**** detects *Borrelia* specific DNA including but not limited to *B. chiliensis*, *B. sinica* and *B. japonica*

DISCLAIMER: Diagnostic value of a negative result is questionable due to low or nonexistent number of Borrelia organisms in patients with Lyme disease

LIMITATION: An inhibition study was performed on about 2000 clinical samples that included fresh whole blood, fresh serum, frozen urine and frozen CSF samples. The inhibition for all sample types was well controlled and only occurred in less than 1% of samples. Therefore, no inhibition control is included in the assay.



End of Report

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, *C. pneumoniae* IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.